<DOC>
	<DOCNO>NCT00091416</DOCNO>
	<brief_summary>The purpose study test safety immune response HIV-1 vaccine , VRC-HIVADV014-00-VP , give vaccine booster HIV uninfected adult participate HVTN 052 .</brief_summary>
	<brief_title>Safety Immune Response HIV-1 Vaccine Boost ( VRC-HIVADV014-00-VP ) HIV Uninfected Adults Who Participated HVTN 052</brief_title>
	<detailed_description>The worldwide HIV epidemic highlight importance develop affordable , globally successful vaccine HIV prevention . The VRC-HIVADV014-00-VP adenoviral vector vaccine use study develop stimulate strong virus-specific CD8 cytotoxic T-lymphocyte ( CTL ) responses think crucial effective preventive HIV vaccine . The purpose study determine safety immunogenicity VRC-HIVADV014-00-VP vaccine boost give healthy , HIV uninfected individual participate HVTN 052 , evaluate VRC-HIVDNA009-00-VP DNA plasmid vaccine . In study , participant receive either 3 injection vaccine , 2 injection vaccine 1 injection placebo , 3 injection placebo 2-month period . This study last one year . Participants randomly assign receive vaccine boost placebo intramuscular injection . The injection give 6 9 month participant 's first HVTN 052 study injection , preferably close 6 month first HVTN 052 injection possible . After screen visit , study visit occur enrollment ( injection give ) , Week 2 , Months 1 , 3 , 6 , 12 . Blood collection , physical exam , medication assessment occur every study visit ; urine collection occur select visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Previously enrol complete 3 study vaccine injection HVTN 052 Understanding vaccination procedure Good general health HIV uninfected Hepatitis B surface antigen negative Antihepatitis C virus ( HCV ) antibody negative , negative HCV PCR antiHCV positive Willing use acceptable form contraception Immunosuppressive medication within 168 day prior study Blood product within 120 day prior study Immunoglobulin within 60 day prior study Live attenuate vaccine within 30 day prior study Investigational research agent within 30 day prior study Medically indicate subunit kill vaccine within 14 day prior study Allergy shot within 30 day prior study Current antituberculosis prophylaxis therapy Anaphylaxis serious adverse reaction vaccine . A person adverse reaction pertussis vaccine child exclude . Autoimmune disease immunodeficiency Active syphilis infection Unstable asthma ( e.g. , daily symptom ; use oral orally inhaled corticosteroid treatment ; emergent care , urgent care , hospitalization , intubation past 2 year ) Diabetes mellitus . A participant past gestational diabetes exclude . Thyroid disease , include removal thyroid diagnose require medication . A participant requiring thyroid medication last year exclude . Serious angioedema . A participant episode angioedema 3 year prior study , required medication least 2 year , exclude . Uncontrolled hypertension Diagnosis bleed disorder Malignancy , except surgical excision reasonable assurance sustain cure and/or unlikely recur period study Seizure disorder require medication within last 3 year Absence spleen Mental illness would interfere compliance protocol Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>